Mabion

Mabion S.A. is a European public CDMO specializing in the development and manufacturing of biologic drugs, with a core history in antibodies and biosimilars. The company is executing a strategic transformation to become a specialized, value-adding partner, evidenced by a growing client roster, strategic alliances (e.g., with Sartorius), and a focus on complex modalities like Antibody-Drug Conjugates (ADCs). While navigating financial stabilization, its goals include reaching break-even by end of 2026, supported by new financing and an expanded international business development team.

End-to-end biologics CDMO platform for mammalian cell culture (CHO), offering cell line development, process development, GMP drug substance manufacturing, analytics, and fill & finish services. Expanding into ADC co-development and leveraging strategic tech partnership with Sartorius.

Operates in the highly competitive global biologics CDMO sector, competing against large players (Lonza, Catalent, Samsung Biologics) and mid-sized specialists. Its differentiation lies in its EU-based, cost-competitive manufacturing, deep antibody expertise, and strategic partnership approach, but it must consistently win bids against well-capitalized rivals.